Phenytoin Dosing: 100mg TDS vs 300mg ON
For maintenance therapy in epilepsy, phenytoin 300mg once nightly is preferred over 100mg three times daily, as both regimens achieve equivalent steady-state serum levels and seizure control while once-daily dosing significantly improves medication adherence.
Evidence Supporting Once-Daily Dosing
The most direct evidence comes from a Class II prospective volunteer study by Buchanan et al, which demonstrated that both 100mg three times daily and 300mg once daily reached identical steady-state serum levels at 7-8 days, with 20% of patients achieving therapeutic levels (>10 mg/L) regardless of dosing method 1. This finding is critical because it establishes pharmacokinetic equivalence between the two regimens.
Additional research in ambulant epileptic patients showed that simplified dosing regimens (once or twice daily) resulted in statistically superior mean blood phenytoin levels compared to more frequent dosing schedules, despite equivalent mg/kg daily doses 2. This difference was attributed to improved drug compliance with less frequent dosing.
A controlled study of 53 epileptic patients found no significant change in seizure frequency or late morning serum phenytoin concentrations when switching from 2-3 spaced doses daily to a single 12:00 noon dose 3. The control group receiving divided doses throughout showed no changes either, confirming that once-daily dosing maintains anticonvulsant efficacy.
FDA-Approved Guidance
The FDA drug label explicitly supports once-daily dosing: "Once-a-day dosage offers a convenience to the individual patient...and is intended to be used only for patients requiring this amount of drug daily" 4. The label specifies that once seizure control is established with divided doses of three 100mg capsules daily, once-a-day dosage with 300mg may be considered. Importantly, only extended phenytoin sodium capsules (Dilantin) are recommended for once-a-day dosing due to their specific dissolution characteristics 4.
Bioequivalence studies confirmed that the 300mg extended phenytoin sodium capsule formulation produces similar Cmax, tmax, and AUC values compared to three 100mg capsules, with equal seizure control maintained 5.
Pharmacokinetic Rationale
Phenytoin's long half-life (averaging 22 hours, range 7-42 hours) makes once-daily dosing pharmacologically sound 4. Steady-state therapeutic levels are achieved at 7-10 days (5-7 half-lives) after initiation with recommended 300mg/day doses 4. This extended half-life allows for sustained therapeutic concentrations throughout a 24-hour dosing interval.
Clinical Advantages of Once-Daily Dosing
- Improved adherence: The major clinical advantage is enhanced medication compliance, particularly important for noncompliant patients 4
- Convenience: Simplified regimen for both outpatients and institutionalized patients
- Equivalent efficacy: No compromise in seizure control
- Same therapeutic range: Both regimens target the 10-20 mcg/mL serum level range
Important Caveats
Formulation matters: Only use extended phenytoin sodium capsules for once-daily dosing. Prompt-release formulations require divided dosing 4
Monitor when switching: When changing dosage forms or brands, closely monitor phenytoin serum levels due to differences in dissolution characteristics 4
Patient counseling: Patients must be cautioned not to inadvertently miss a dose with once-daily regimens 4
Steady-state timing: Allow 7-10 days to reach steady state before making dosage adjustments 4
Individual variability: While most patients do well with standard dosing, some may require serum level monitoring due to wide interpatient variability in metabolism 4
In summary, phenytoin 300mg once nightly is the preferred maintenance regimen over 100mg three times daily, provided extended-release formulations are used and patients are counseled about adherence. The once-daily approach maintains equivalent therapeutic efficacy while substantially improving real-world medication compliance, which is critical for preventing breakthrough seizures in epilepsy management 1, 4, 2, 3.